ethanol, 2-(5H-dibenzo[a,d]cyclohepten-5-yloxy)- | 110283-58-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 二苯并环庚烯
• 英文名称: ethanol, 2-(5H-dibenzo[a,d]cyclohepten-5-yloxy)-
• 英文别名: 2-(5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethanol；2-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenyloxy)ethanol
• CAS: 110283-58-4
• 化学式: C₁₇H₁₆O₂
• 分子量: 252.313
• InChiKey: BPBUNJJMXWHIHS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  ethanol, 2-(5H-dibenzo[a,d]cyclohepten-5-yloxy)- 在 potassium carbonate 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 15.5h， 生成 1-[2-(5H-Dibenzo[a,d]cyclohepten-5-yloxy)-ethyl]-piperidine-3-carboxylic acid ethyl ester
  参考文献：
  名称：

  Structure-activity studies on benzhydrol-containing nipecotic acid and guvacine derivatives as potent, orally-active inhibitors of GABA uptake

  摘要：

  The introduction of lipophilic groups onto the ring nitrogen of nipecotic acid and guvacine, two known GABA uptake inhibitors, afforded potent, orally-active anticonvulsant drugs. A series of compounds is reported which explores the structure-activity relationships (SAR) in this series. Among the areas explored: side-chain SAR (aromatic-, heterocyclic-, and tricyclic-containing side chains) and modifications to the tetrahydropyridine ring. The benzhydrol ether-containing side chains afforded the most potent compounds with several exhibiting in vitro IC50 values for GABA uptake of <1 muM (including 5, Table 1; 37, 43, Table IV; and 44, Table V). Compound 44 was selected for extensive evaluation and subsequently progressed to Phase 1 clinical trials with severe adverse effects seen after single dose administration to humans.

  DOI：

  10.1021/jm00100a032
• 作为产物：
  描述：

  5-二苯并环庚烯酮 在 sodium tetrahydroborate 、 lithium aluminium tetrahydride 、 sodium hydride 作用下， 以 四氢呋喃 、 乙醚 、 异丙醇 为溶剂， 反应 51.5h， 生成 ethanol, 2-(5H-dibenzo[a,d]cyclohepten-5-yloxy)-
  参考文献：
  名称：

  Structure-activity studies on benzhydrol-containing nipecotic acid and guvacine derivatives as potent, orally-active inhibitors of GABA uptake

  摘要：

  The introduction of lipophilic groups onto the ring nitrogen of nipecotic acid and guvacine, two known GABA uptake inhibitors, afforded potent, orally-active anticonvulsant drugs. A series of compounds is reported which explores the structure-activity relationships (SAR) in this series. Among the areas explored: side-chain SAR (aromatic-, heterocyclic-, and tricyclic-containing side chains) and modifications to the tetrahydropyridine ring. The benzhydrol ether-containing side chains afforded the most potent compounds with several exhibiting in vitro IC50 values for GABA uptake of <1 muM (including 5, Table 1; 37, 43, Table IV; and 44, Table V). Compound 44 was selected for extensive evaluation and subsequently progressed to Phase 1 clinical trials with severe adverse effects seen after single dose administration to humans.

  DOI：

  10.1021/jm00100a032

文献信息

• Compounds, their preparation and use
  申请人：Novo Nordisk A/S

  公开号：US06214820B1

  公开（公告）日：2001-04-10

  The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, A, X, T, Q, Z, U, Y, Ar, p and n are as defined in the specification. These compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).

  本发明涉及式（I）的化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、A、X、T、Q、Z、U、Y、Ar、p和n如规范中定义。这些化合物在治疗和/或预防由核受体介导的疾病中有用，特别是过氧化物酶体增殖激活受体（PPAR）。
• Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR)
  申请人：Novo Nordisk A/S

  公开号：US06248781B1

  公开（公告）日：2001-06-19

  The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, Ar, X, Q, A, Y and Z are as defined in the specification. These compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).

  本发明涉及式(I)的化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、Ar、X、Q、A、Y和Z如规范中所定义。这些化合物在治疗和/或预防由核受体介导的疾病中具有用途，特别是过氧化物酶体增殖激活受体（PPAR）。
• New compounds, their preparation and use
  申请人：——

  公开号：US20010029256A1

  公开（公告）日：2001-10-11

  The present invention relates to compounds of formula (I) 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , A, X, T, Q, Z, U, Y, Ar, p and n are as defined in the specification. These compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).

  本发明涉及式(I)1的化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、A、X、T、Q、Z、U、Y、Ar、p和n的定义如规范中所述。这些化合物在治疗和/或预防由核受体介导的疾病中有用，特别是过氧化物酶体增殖物激活受体（PPAR）。
• Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors(PPAR)
  申请人：——

  公开号：US20010031764A1

  公开（公告）日：2001-10-18

  The present invention relates to compounds of formula (I) 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , Ar, X, Q, A, Y and Z are as defined in the specification. These compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).

  本发明涉及式(I)化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、Ar、X、Q、A、Y和Z的定义如规范中所述。这些化合物在治疗和/或预防通过核受体介导的疾病中有用，特别是过氧化物酶体增殖物激活受体（PPAR）。
• PAVIA, MICHAEL R.
  作者：PAVIA, MICHAEL R.

  DOI：——

  日期：——